NEW YORK, Sept. 21, 2012 /CNW/ - Anavex Life Sciences Corp. ("Anavex")
(OTCQB: AVXL) today joins the Alzheimer's Association® in recognizing
September 21st as Alzheimer's Action Day.
September is World Alzheimer's Month. In the United States alone,
Alzheimer's disease afflicts more than five million people and affects
millions more husbands, wives, children, grandchildren, and
caregivers. By 2050, the Alzheimer's Association® projects that $1
trillion will be required to treat as many as 16 million Americans
suffering from this disease. Anavex encourages you to learn more about
Alzheimer's disease and the impact it has on you, your family and
friends today, and its impact in the future.
Early detection can help individuals get the most effectiveness from
currently available treatments and to maintain their independence for a
longer period of time. The Alzheimer's Association® has published information so that you and your loved ones can learn more about early signs of
this disease, which include memory loss that disrupts daily life,
difficulty completing familiar tasks and confusion with time or place.
Anavex is researching a cure for Alzheimer's disease and supports
efforts to raise awareness, and reduce the stigma of this disease. We
encourage you to take some time today to learn more about Alzheimer's
disease and to talk to your loved ones. Your discussion may help
prevent you or a loved one from mistaking early signs of the disease
with normal signs of aging. To learn more visit the Alzheimer's
Association® web site at www.alz.org.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a pharmaceutical company engaged in the development of novel drug
candidates. Lead compound ANAVEX 2-73, developed to treat Alzheimer's
through disease modification, is in human clinical trials. A Phase 1
single ascending dose study of ANAVEX 2-73 was successfully completed
in Germany in 2011. Studies indicate that ANAVEX 2-73 demonstrates
anti-amnesic and neuroprotective properties, and that it is well
tolerated in doses up to 55mg. The company is preparing to embark on a
multiple ascending dose clinical trial of ANAVEX 2-73 in 2012. Anavex
is a publicly traded corporation quoted as AVXL.
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in drug
discovery and development, which include, without limitation, the
potential failure of development candidates to advance through
preclinical studies or demonstrate safety and efficacy in clinical
testing and the ability to pass clinical trials so as to move on to the
next phase, our ability to finance development or satisfy the rigorous
regulatory requirements for new drugs, our ability to attract and
retain quality personnel, and that despite positive results, our
competitors may offer better or cheaper alternatives. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Anavex Life Sciences Corp. undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof.
SOURCE: Anavex Life Sciences Corp.
For further information:
Anavex Life Sciences Corp.
Research & Business Development
Shareholder & Media Relations
Outside North America: +1 (416) 489-0092